A recent trial sought to assess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor–positive (HR+), HER2-negative advanced ...

Please provide your email address to receive an email when new articles are posted on . The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast ...

Credit: AstraZeneca. The approval was based on data from the phase 3 CAPItello-291 trial, which included patients with HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN ...

Credit: Getty Images. Capivasertib is a potential first-in-class AKT inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for capivasertib ...

Please provide your email address to receive an email when new articles are posted on . Fulvestrant in combination with everolimus extended PFS significantly longer than fulvestrant with vistusertib ...

CHICAGO -- Adding investigational capivasertib to fulvestrant extended survival in patients with aromatase inhibitor-resistant estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, ...

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...

BLOOMINGTON, Ind. -- Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington ...

Following is a transcript of their remarks: Rugo: Hello. I'm Hope Rugo, a professor of medicine and director of Breast Oncology in Clinical Trials Education at the University of California San ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Patel et al 1 eloquently present compelling evidence that 250 mg of fulvestrant may be a sufficient dose in resource-limited settings. Their work highlights the disparity between cost and efficacy of ...

Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, fulvestrant and anastrozole, compared with treatment with ...